Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: KIPPer who wrote (2532)	7/4/1998 8:44:00 PM
From: chirodoc	Read Replies (3) \| Respond to of 5402

valuation is very difficult in biotech. the value of a company cannot be assess by price/earnings or price to sales because their aren't any. the value is a ratio of the inveestment community's perception of their molecules + the float + the management. take a look at xoma for example--might be better than ENMD because xoma has been around for a long time, has no products, and basically has one molecule. you will see the price has risen and fallen based on the public's perception of the value of the company. what will happen with sgnc is that the price will eventually stabilize in a very consistent zone based upon investor perception. as clinical trials unfold the price will rise and fall based on the results of those studies. luckily for us, this molecule has alread been tried on aniumals and humans and we understand its' effect. phase I should be easy because it basically just tests toxicity and we already know what dose is effective and how much is safe. so, we should see rise in price when dr. d. gets press coverage or their are some results from testing. curtis